minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Company profile
Ticker
NERV
Exchange
Website
CEO
Remy Luthringer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Mind-NRG Sarl • Minerva Neurosciences Securities Corporation ...
NERV stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
22 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Apr 24
8-K
Other Events
27 Feb 24
10-K/A
2023 FY
Annual report (amended)
23 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
28 Sep 23
ARS
2022 FY
Annual report to shareholders
15 Aug 23
DEFA14A
Additional proxy soliciting materials
15 Aug 23
DEF 14A
Definitive proxy
15 Aug 23
Transcripts
NERV
Earnings call transcript
2023 Q1
15 May 23
NERV
Earnings call transcript
2022 Q4
8 Mar 23
NERV
Earnings call transcript
2022 Q3
9 Nov 22
NERV
Earnings call transcript
2021 Q3
8 Nov 21
NERV
Earnings call transcript
2021 Q2
2 Aug 21
NERV
Earnings call transcript
2021 Q1
12 May 21
NERV
Earnings call transcript
2020 Q4
8 Mar 21
NERV
Earnings call transcript
2020 Q3
2 Nov 20
NERV
Earnings call transcript
2020 Q2
3 Aug 20
NERV
Earnings call transcript
2020 Q1
4 May 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 47.00 mm | 47.00 mm | 47.00 mm | 47.00 mm | 47.00 mm | 47.00 mm |
Cash burn (monthly) | 1.63 mm | (no burn) | 2.03 mm | 1.75 mm | 1.60 mm | 1.08 mm |
Cash used (since last report) | 11.13 mm | n/a | 13.82 mm | 11.95 mm | 10.93 mm | 7.34 mm |
Cash remaining | 35.88 mm | n/a | 33.18 mm | 35.06 mm | 36.08 mm | 39.67 mm |
Runway (months of cash) | 22.0 | n/a | 16.4 | 20.0 | 22.5 | 36.9 |
Institutional ownership, Q2 2023
55.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 4 |
Closed positions | 2 |
Increased positions | 7 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 17.75 bn |
Total shares | 3.85 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AG Boehringer | 1.50 mm | $9.03 mm |
FHI Federated Hermes Inc - Ordinary Shares | 1.35 mm | $9.90 bn |
FMR | 491.75 k | $4.49 bn |
Vanguard | 205.15 k | $1.88 bn |
Renaissance Technologies | 98.30 k | $898.00 k |
BLK Blackrock | 78.83 k | $720.52 mm |
Geode Capital Management | 51.96 k | $474.95 mm |
Acadian Asset Management | 21.46 k | $195.00 k |
VIRT Virtu Financial | 20.99 k | $192.00 k |
STT State Street | 13.72 k | $125.39 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Oct 23 | Ahlholm Frederick W | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.41 | 42,850 | 274.67 k | 42,850 |
4 Oct 23 | Geoff Race | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.41 | 87,050 | 557.99 k | 87,050 |
4 Oct 23 | Remy Luthringer | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.41 | 100,450 | 643.88 k | 100,450 |
27 Sep 23 | Kupfer David | Stock Option Common Stock | Grant | Acquire A | No | No | 7.3 | 12,500 | 91.25 k | 12,500 |
27 Sep 23 | Laghrissi-Thode Fouzia | Stock Option Common Stock | Grant | Acquire A | No | No | 7.3 | 12,500 | 91.25 k | 12,500 |
News
Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings
27 Feb 24
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
27 Feb 24
Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data
27 Feb 24
HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $11 Price Target
27 Feb 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
27 Feb 24